Argus Investors' Counsel, Inc. Incyte Corp Transaction History

Argus Investors' Counsel, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 19, 2021	SELL	$76.02 - $100.5 $509,790 - $673,953	-6,706 Closed	0 $0
Q4 2020 Jan 27, 2021	BUY	$80.74 - $97.7 $10,415 - $12,603	129 Added 1.96%	6,706 $583,000
Q3 2020 Oct 30, 2020	BUY	$85.07 - $109.69 $559,505 - $721,431	6,577 New	6,577 $590,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Argus Investors' Counsel, Inc., based on Form 13F filings with the SEC.

Stay updated on Argus Investors' Counsel, Inc. with notifications on news.